Diabetes Care, Vol 19, Issue 11 1194-1199, Copyright © 1996 by American Diabetes Association

ARTICLES

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group

J Rosenstock, E Samols, DB Muchmore and J Schneider
Dallas Diabetes and Endocrine Center, TX 75230, USA.

OBJECTIVE: To compare the efficacy and safety of two daily doses of the new sulfonylurea, glimepiride (Amaryl), each as a once-daily dose or in two divided doses, in patients with NIDDM. RESEARCH DESIGN AND METHODS: Of the previously treated NIDDM patients, 416 entered this multicenter randomized double-blind placebo-controlled fixed-dose study. After a 3-week placebo washout, patients received a 14-week course of placebo or glimepiride 8 mg q.d., 4 mg b.i.d., 16 mg q.d., or 8 mg b.i.d. RESULTS: Fasting plasma glucose (FPG) and HbA1c values were similar at baseline in all treatment groups. The placebo group's FPG value increased from 13.0 mmol/l at baseline to 14.5 mmol/l at the last evaluation endpoint (P < or = 0.001). In contrast, FPG values in the four glimepiride groups decreased from a range of 12.4-12.9 mmol/l at baseline to a range of 8.6-9.8 mmol/l at endpoint (P < or = 0.001, within-group change from baseline; P < or = 0.001, between-group change [vs. placebo] from baseline). Two-hour postprandial plasma glucose (PPG) findings were consistent with FPG findings. In the placebo group, the HbA1c value increased from 7.7% at baseline to 9.7% at endpoint (P < or = 0.001), whereas HbA1c values for the glimepiride groups were 7.9-8.1% at baseline and 7.4-7.6% at endpoint (P < or = 0.001, within-group change from baseline; P < or = 0.001, between-group change from baseline). There were no meaningful differences in glycemic variables between daily doses of 8 and 16 mg or between once- and twice-daily dosing. Adverse events and laboratory data demonstrate that glimepiride has a favorable safety profile. CONCLUSIONS: Glimepiride is an effective and well-tolerated oral glucose-lowering agent. The results of this study demonstrate maximum effectiveness can be achieved with 8 mg q.d. of glimepiride in NIDDM subjects.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Selvin, S. Bolen, H.-C. Yeh, C. Wiley, L. M. Wilson, S. S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E. B. Bass, et al. Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review Arch Intern Med, October 27, 2008; 168(19): 2070 - 2080. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Approaches to Treatment of Type 2 Diabetes Diabetes Care, August 1, 2008; 31(8): 1697 - 1703. [Full Text] [PDF]

				C. Triplitt, L. Glass, Y. Miyazaki, E. Wajcberg, A. Gastaldelli, E. De Filippis, E. Cersosimo, and R. A. DeFronzo Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care, November 1, 2006; 29(11): 2371 - 2377. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				I. B. Hirsch, R. M. Bergenstal, C. G. Parkin, E. Wright Jr., and J. B. Buse A Real-World Approach to Insulin Therapy in Primary Care Practice Clin. Diabetes, April 1, 2005; 23(2): 78 - 86. [Full Text] [PDF]

				C. Abletshauser, P. Brunel, K.-H. Usadel, and M. Hanefeld Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 93 - 99. [Abstract] [PDF]

				U. A Shukla, E. M Chi, and K.-H. Lehr Glimepiride Pharmacokinetics in Obese Versus Non-Obese Diabetic Patients Ann. Pharmacother., January 1, 2004; 38(1): 30 - 35. [Abstract] [Full Text] [PDF]

				S. Gahagan, J. Silverstein, Committee on Native American Child Health, and Section on Endocrinology Prevention and Treatment of Type 2 Diabetes Mellitus in Children, With Special Emphasis on American Indian and Alaska Native Children Pediatrics, October 1, 2003; 112(4): e328 - e328. [Abstract] [Full Text] [PDF]

				A. D. Morris Addressing Dosing Frequency in Diabetes: A Simple Approach to Improving Adherence to Therapy and Clinical Outcomes The Diabetes Educator, May 1, 2003; 29(3): 440 - 453. [PDF]

				A. Haupt, C. Kausch, D. Dahl, O. Bachmann, M. Stumvoll, H.-U. Haring, and S. Matthaei Effect of Glimepiride on Insulin-Stimulated Glycogen Synthesis in Cultured Human Skeletal Muscle Cells: A comparison to glibenclamide Diabetes Care, December 1, 2002; 25(12): 2129 - 2132. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				P. A. Hollander, S. L. Schwartz, M. R. Gatlin, S. J. Haas, H. Zheng, J. E. Foley, and B. E. Dunning Importance of Early Insulin Secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes Diabetes Care, June 1, 2001; 24(6): 983 - 988. [Abstract] [Full Text]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]